SCHEMBL5830689

SCHEMBL5830689

O=C(Cc1nsc(NS(=O)(=O)c2c(Cl)cc(Cl)cc2Cl)n1)N1CCOCC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.71
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 3/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
POLB P06746 2/20 0.38
ACLY P53396 1/20 0.37
SCN9A Q15858 1/20 0.37
FKBP1A P62942 1/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5830857 0.93 HSD11B1 (0.62) HSD11B1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5831048 0.91 HSD11B1 (0.59) HSD11B1KMT2AALDH1A1GAAACLY
SCHEMBL5831436 0.90 HSD11B1 (0.56) HSD11B1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5831094 0.89 HSD11B1 (0.56) HSD11B1KMT2AKDM4EALDH1A1SCN9A
SCHEMBL5831838 0.87 HSD11B1 (0.55) HSD11B1KMT2AKDM4ESMN1; SMN2MEN1
SCHEMBL5830800 0.84 HSD11B1 (0.51) HSD11B1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL5832090 0.83 HSD11B1 (0.51) HSD11B1KMT2AKDM4ESMN1; SMN2MAPT
SCHEMBL5830658 0.83 HSD11B1 (0.50) HSD11B1KMT2ASMN1; SMN2ALDH1A1MEN1
SCHEMBL3621000 0.83 HSD11B1 (1.00) HSD11B1KMT2AKDM4EALDH1A1GAA
SCHEMBL5830646 0.83 HSD11B1 (0.50) HSD11B1KMT2AKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US claimed
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 HSD11B1 2/4885KMT2A 2980/4885KDM4E 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.